Cargando…

The role of local radiotherapy following rituximab‐containing chemotherapy in patients with transformed indolent B‐cell lymphoma

OBJECTIVES: This study aimed to evaluate the outcomes of local radiotherapy (LRT) in patients with histologic transformation (HT) following rituximab‐containing chemotherapy. METHODS: We retrospectively analysed 92 patients with biopsy‐confirmed HT undergoing rituximab‐containing chemotherapy at our...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nozaki, Kenji, Maruyama, Dai, Maeshima, Akiko Miyagi, Tajima, Kinuko, Itami, Jun, Shichijo, Takafumi, Yuda, Sayako, Suzuki, Tomotaka, Toyoda, Kosuke, Yamauchi, Nobuhiko, Makita, Shinichi, Fukuhara, Suguru, Munakata, Wataru, Kobayashi, Yukio, Taniguchi, Hirokazu, Izutsu, Koji, Tobinai, Kensei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894292/ https://www.ncbi.nlm.nih.gov/pubmed/33098704 http://dx.doi.org/10.1111/ejh.13539

Ejemplares similares

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2020)

Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016)

Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
por: Ito, Yuta, et al.
Publicado: (2018)

Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
por: Makita, Shinichi, et al.
Publicado: (2017)

Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors
por: Suzuki, Tomotaka, et al.
Publicado: (2020)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
por: Nakai, Ritsuko, et al.
Publicado: (2019)

Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
por: Makita, Shinichi, et al.
Publicado: (2018)

The outcome of watchful waiting in patients with previously treated follicular lymphoma
por: Fujino, Takahiro, et al.
Publicado: (2022)

A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia
por: Izutsu, Koji, et al.
Publicado: (2020)

Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era
por: Kawajiri, A, et al.
Publicado: (2016)

Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases
por: Okuma, Hitomi Sumiyoshi, et al.
Publicado: (2016)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2015)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2017)

FUS-ERG gene fusion in isolated myeloid sarcoma showing uncommon clinical features
por: Ueda, Ryosuke, et al.
Publicado: (2016)

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
por: Munakata, Wataru, et al.
Publicado: (2019)

Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
por: Munakata, Wataru, et al.
Publicado: (2022)

Clinical development of anti‐CD19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2017)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

The role of surveillance computed tomography in patients with follicular lymphoma
por: Hatta, Shunsuke, et al.
Publicado: (2022)

COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma
por: Hosoba, Rika, et al.
Publicado: (2020)

Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma
por: Tanimoto, Kazuki, et al.
Publicado: (2006)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
por: Makita, Shinichi, et al.
Publicado: (2019)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
por: Nomoto, Junko, et al.
Publicado: (2012)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
por: Fukuhara, Noriko, et al.
Publicado: (2022)

Too much and not enough: revisiting maintenance rituximab in indolent lymphomas
por: Smith, Sonali M.
Publicado: (2021)

Diffuse large B-cell lymphoma with composite germinal center and non-germinal center types: A report of two cases
por: Sugitani, Ayumi, et al.
Publicado: (2023)

Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
por: Ogura, Michinori, et al.
Publicado: (2015)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab
por: Menzer, Christian, et al.
Publicado: (2022)

CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
por: Kagiyama, Yuki, et al.
Publicado: (2021)

Clinical Trials and Treatment of ATL
por: Tsukasaki, Kunihiro, et al.
Publicado: (2012)

P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
por: Kumode, Takahiro, et al.
Publicado: (2023)

Hyper‐intense lesion in the pons on brain magnetic resonance imaging in a patient with diffuse large B‐cell lymphoma
por: Saito, Yo, et al.
Publicado: (2021)

Mitochondrial dysfunction in cumulus-oocyte complexes increases cell-free mitochondrial DNA
por: KANSAKU, Kazuki, et al.
Publicado: (2018)

Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
por: Negoro, Eiju, et al.
Publicado: (2023)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ca82ibcbgt4j0380iu3r5o7ov